Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network.
Journal: Journal Of The Pediatric Infectious Diseases Society
Published:
Abstract
Of 319 children with invasive candidiasis, 67 (21%) transitioned from intravenous to enteral antifungal therapy. Eight (12%) transitioned back to intravenous antifungal therapy, one due to perceived treatment failure defined by clinical progression or worsening. Global treatment response at study completion was successful in 66 participants who transitioned to enteral therapy.
Authors
Robert F Bucayu, Craig L Boge, Inci Yildirim, Martha Avilés Robles, Surabhi Vora, David Berman, Tanvi Sharma, Lillian Sung, Elio Castagnola, Debra Palazzi, Lara Danziger Isakov, Dwight Yin, Emmanuel Roilides, Gabriela Maron, Alison Tribble, Pere Soler Palacin, Eduardo López Medina, José Romero, Kiran Belani, Antonio Arrieta, Fabianne Carlesse, Dawn Nolt, Natasha Halasa, Daniel Dulek, Sujatha Rajan, William Muller, Monica Ardura, Alice Pong, Blanca Gonzalez, Christine Salvatore, Anna Huppler, Catherine Aftandilian, Mark Abzug, Arunaloke Chakrabarti, Michael Green, Irja Lutsar, Elizabeth Knackstedt, Sarah Johnson, William Steinbach, Brian Fisher, Rachel Wattier